SCLC Clinical Trial - Observational Study to Evaluate the Safety &

See also
Status	Clinical Trial	Phase
Completed	`NCT05026593` - A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Phase 1
Active, not recruiting	`NCT03575793` - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT05903092` - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT00046787` - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer	Phase 2
Suspended	`NCT04826341` - A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors	Phase 1/Phase 2
Recruiting	`NCT05655598` - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer	Phase 1
Withdrawn	`NCT04677361` - Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab	Early Phase 1
Terminated	`NCT00522639` - Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation	Phase 3
Completed	`NCT03428607` - Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]	Phase 2
Recruiting	`NCT05546268` - Study of Oral MRT-2359 in Selected Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT06116019` - Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Not yet recruiting	`NCT03244904` - Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment	N/A
Completed	`NCT01713296` - Pazopanib in Relapsed and Refractory Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04162041` - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer	Phase 2
Recruiting	`NCT05130255` - GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2	Phase 1
Recruiting	`NCT04686682` - A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors	Phase 1/Phase 2
Recruiting	`NCT02611024` - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05879068` - A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC	Phase 2
Recruiting	`NCT04684017` - Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer	Phase 2
Completed	`NCT00346385` - BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors	Phase 1

NCT number	NCT06021483
Study type	Observational
Source	Boryung Pharmaceutical Co., Ltd
Contact	Shinyoung Oh
Phone	+82-2-708-8000
Email	syoh@boryung.co.kr
Status	Recruiting
Phase
Start date	August 16, 2023
Completion date	September 2025

Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms